MAP2K4 and neoplasm: Consistent with our in vitro and in vivo findings, PDX models having mutations in MAP3K1 or MAP2K4 were significantly more sensitive to binimetinib than their wild type counterparts, with only the mutant tumors showing a decrease in tumor volume over time (Fig. 6d, p = 0.0023).